Utama › Dermatitis Atopik (Eksim) › Alabama
Kajian klinikal Dermatitis Atopik (Eksim) di Alabama
9 kajian untuk Dermatitis Atopik (Eksim) sedang mencari peserta di lokasi di Alabama.
Bandar di Alabama
Teks kajian rasmi (Bahasa Inggeris)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
Mengambil pesertaKajian pemerhatian
Umur 12 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 65 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
Mengambil pesertaFasa 3
Umur 2 hingga 11 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
Mengambil pesertaFasa 3
6 Months – 11 Years · Semua jantina · Dikemas kini 7 Jul 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
Mengambil pesertaFasa 3
Umur 18 hingga 63 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mei 2026 · NCT05995964Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.